- Home
- MIRM vs CHE Comparison
MIRM vs CHE Comparison
Compare MIRM & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | CHE |
|---|---|---|
| Founded | 2018 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.7B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MIRM | CHE |
|---|---|---|
| Price | $82.85 | $520.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 5 |
| Target Price | $153.07 | ★ $571.60 |
| AVG Volume (30 Days) | ★ 732.8K | 118.9K |
| Earning Date | 11-03-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ 9.97 |
| Revenue | $19,138,000.00 | ★ $2,529,978,000.00 |
| Revenue This Year | $33.62 | $7.56 |
| Revenue Next Year | $17.72 | $6.05 |
| P/E Ratio | ★ N/A | $51.15 |
| Revenue Growth | N/A | ★ 4.06 |
| 52 Week Low | $63.23 | $365.21 |
| 52 Week High | $130.00 | $557.00 |
Technical Indicators
Market Signals| Indicator | MIRM | CHE |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 56.88 |
| Support Level | $78.07 | $495.72 |
| Resistance Level | $88.31 | $553.35 |
| Average True Range (ATR) | 3.94 | 10.24 |
| MACD | 0.69 | 1.87 |
| Stochastic Oscillator | 46.34 | 90.70 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About CHE Chemed Corp
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.